Cancer vaccines represent a novel approach in cancer treatment, leveraging the body’s immune system to identify and eradicate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate an immune response against specific proteins found on cancer cells, potentially preventing cancer recurrence and impeding tumor progression. Recent strides in personalized medicine have facilitated the development of tailored cancer vaccines, which target individual tumor characteristics, thereby enhancing efficacy while minimizing adverse effects. Despite some setbacks in the past, ongoing research in immunotherapy, including cancer vaccines, remains a focal point of interest at this year’s AACR conference.
|
Company
|
Drug
|
Indication
|
Trial Acronym
|
Phase
|
Abstract
|
Abstract Title
|
|
PDC*line Pharma
|
PDC*lung01
|
NSCLC
|
NCT03970746
|
I/II
|
CT021
|
Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC
|
|
Elicio Therapeutics
|
ELI-002 2P
|
Pancreatic cancer
|
AMPLIFY-201 (NCT04853017)
|
I
|
CT022
|
Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study
|
|
Oncovir
|
Neoadjuvant Hiltonol (PolyICLC)
|
Prostate
Cancer
|
NCT03262103
|
I
|
CT023
|
Prostate cancer in situ autovaccination with the intratumoral viral mimic poly-ICLC: Making a cold tumor hot.
|
|
Scancell
|
SCIB1
|
Advanced unresectable melanoma
|
SCOPE
(NCT04079166)
|
II
|
CT024
|
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial
|
|
BioSante
|
GVAX
|
Pancreatic adenocarcinoma
|
NCT03153410
|
Early Phase I
|
CT134
|
Safety and immunologic impact of neoadjuvant/adjuvant GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) combined with cyclophosphamide, pembrolizumab, and macrophage-targeting CSF1R inhibitor IMC-CS4 in pancreatic adenocarcinoma
|
|
Genentech
|
Autogene cevumeran (RO7198457, RG6180)
|
Pancreatic ductal
adenocarcinoma (PDAC)
|
NCT05968326
|
II
|
CT025
|
Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer
|
|
Syncromune
|
SV-102
|
Metastatic castrate-resistant prostate cancer (mCRPC)
|
NCT05544227
|
I
|
CT026
|
Systemic responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)
|
For more information on Cancer Vaccines market, refer to DelveInsight’s report: Cancer Vaccines – Market Insight, Epidemiology and Market Forecast – 2032
